Tumour Angiogenesis and Microenvironment Program, Peter MacCallum Cancer Centre, 305 Grattan St., Melbourne, VIC 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia.
Biomolecules. 2018 Jan 4;8(1):1. doi: 10.3390/biom8010001.
Blood vessels and lymphatic vessels are located in many tissues and organs throughout the body, and play important roles in a wide variety of prevalent diseases in humans. Vascular endothelial growth factor-D (VEGF-D) is a secreted protein that can promote the remodeling of blood vessels and lymphatics in development and disease. Recent fundamental and translational studies have provided insight into the molecular mechanisms by which VEGF-D exerts its effects in human disease. Hence this protein is now of interest as a therapeutic and/or diagnostic target, or as a potential therapeutic agent, in a diversity of indications in cardiovascular medicine, cancer and the devastating pulmonary condition lymphangioleiomyomatosis. This has led to clinical trial programs to assess the effect of targeting VEGF-D signaling pathways, or delivering VEGF-D, in angina, cancer and ocular indications. This review summarizes our understanding of VEGF-D signaling in human disease, which is largely based on animal disease models and clinicopathological studies, and provides information about the outcomes of recent clinical trials testing agonists or antagonists of VEGF-D signaling.
血管和淋巴管位于人体的许多组织和器官中,在人类多种常见疾病中发挥着重要作用。血管内皮生长因子-D(VEGF-D)是一种分泌蛋白,可促进发育和疾病过程中血管和淋巴管的重塑。最近的基础和转化研究提供了深入了解 VEGF-D 在人类疾病中发挥作用的分子机制。因此,该蛋白作为治疗和/或诊断靶点,或作为治疗剂,在心血管医学、癌症和破坏性肺部疾病淋巴管平滑肌瘤病等多种适应症中具有潜在的应用价值。这导致了临床试验项目的开展,以评估针对 VEGF-D 信号通路的靶向治疗或 VEGF-D 递送在心绞痛、癌症和眼部适应证中的效果。本综述总结了我们对 VEGF-D 在人类疾病中的信号作用的理解,这主要基于动物疾病模型和临床病理研究,并提供了关于最近临床试验测试 VEGF-D 信号激动剂或拮抗剂的结果信息。